• This study provides further evidence of similar efficacy and safety between direct oral anti-Xa inhibitors and
    warfarin in morbidly obese patients with AF
  • In patients with AF, warfarin was associated with higher rates of major bleeding compared to rivaroxaban;
    associations became non-significant when adjusted for age, Charlson score, and CHA2DS2-VASc score
    • Authors suggest individual HCP bias for selecting a given OAC according to perceived risk
  • Although the overall low incidence of events in this study population was reassuring, a randomized controlled
    trial is needed to enable patients with morbid obesity to benefit from more convenient therapies, which might
    also offer a net clinical benefit